A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body - Drug Trials For Money

Experimental: Domvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)

Participants in this arm will receive Domvanalimab and zimberelimab doses once every 4 weeks (Q4W) in addition to chemotherapy with FOLFOX (oxaliplatin, leucovorin, fluorouracil) once every 2 weeks (Q2W) or Domvanalimab and zimberelimab once every 3 weeks (Q3W) in addition to chemotherapy with CAPOX (capecitabine and oxaliplatin) Q3W.

Drug: Zimberelimab

Intravenous (IV) Aqueous Solution

Other Name: AB122

Drug: Domvanalimab

IV Aqueous Solution

Other Name: AB154

Drug: Oxaliplatin

IV Aqueous Solution

Drug: Leucovorin

IV Aqueous Solution

Drug: Fluorouracil

IV Aqueous Solution

Drug: Capecitabine

Oral Tablets

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.